media – Page 519 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Janssen Closes in on Seeking FDA Approval for Ketamine-Based Depression Treatment

Janssen Pharmaceuticals is eying a potential breakthrough in treating refractory major depressive disorder. The company plans to seek regulatory approval for its ketamine-based esketamine nasal spray this year and if given the green light it will be the first new approach for the indication in nearly 50 years.
- Source: biospace
- 579
- May 11, 2018
depressive disorder Janssen
Safer HIV drugs taken off the shelf by Gilead

It has been stated by the patients that Gilead concealed crucial information that the TDF drugs could trigger kidney and bone risks. A safer alternative in the form of TAF could have been incorporated while marketing Truvada and Atripla. The research into TAF was deliberately stopped and the drugs are not likely to be brought to the shelf in the near future.
- Source: drugdu
- 862
- May 11, 2018
Company Insights Gilead HIV
New Ebola outbreak declared in Democratic Republic of the Congo

The Government of the Democratic Republic of the Congo declared a new outbreak of Ebola virus disease (EVD) in Bikoro in Equateur Province today (8 May). The outbreak declaration occurred after laboratory results confirmed two cases of EVD.
- Source: WHO
- 591
- May 10, 2018
Ebola Researches
U.S Doctor trust Biogen and Bristol-Myers Squibb

The questionnaire raised queries on the basis of key parameters like empathy for healthcare providers, quality content and motivation for patients. However, qualities like credible scientific content and values not related to promotional activities emerged as strong criterion for building trust.
- Source: fiercepharma
- 665
- May 10, 2018
digital health Market Views Researches
MiMedx shares falls by 20%

The US-Based MiMedx group's (a manufacturer of regenerative medicine) shares fell 20% after the federal prosecutors charged three healthcare professional for accepting bribes from Mimedx. Of these shares, 7.5% recovered when closing for the day.
- Source: drugdu
- 494
- May 10, 2018
Company Insights
Funds of £1.5 million raised by UK-based life sciences group

With a view to augment business activities and help improve product outreach; a UK-based life sciences firm has raised £1.5 million.
- Source: drugdu
- 830
- May 10, 2018
antibody Company Insights
Lynparza tablets (ovarian cancer) given go-ahead by European regulators

With a view to widening the scope of treatment for ovarian cancer patients, EU regulators have greenlighted MSD’s Lynparza and stamped approval for a new dosing regimen and tablet formulation for AstraZeneca.
- Source: drugdu
- 751
- May 10, 2018
AstraZeneca cancer New Approvals pharma
AstraZeneca continues yard-sale strategy with $538M Seroquel rights deal

AstraZeneca is back at it again with asset sales. The company, which has taken some flak for a series of deals to offload asset rights, inked an agreement with Luye Pharma for legacy antipsychotic Seroquel and an extended-release version.
- Source: fiercepharma
- 677
- May 10, 2018
AstraZeneca Seroquel
Johnson & Johnson’s Darzalex snags landmark myeloma approval in first-line patients

EHR vendor Allscripts has made an agreement to purchase patient communication app maker Health Grid for $60 million in cash, with an additional $50 million in earnout payments based on Health Grid achieving certain revenue targets over the next three years, according to a recently registered SEC filing. The merger of the two companies is expected to close sometime during Q2 2018.
- Source: fiercepharma
- 577
- May 10, 2018
Darzalex Johnson & Johnson myeloma
World’s first Train Hospital helping rural Indian population

The Lifeline Express was introduced to meet two gaps: giving medical treatment in the remotest villages and providing lower-income people with free treatment. The train runs all over India, reaching the remotest places and halting in one place for a month before proceeding.
- Source: Ddu
- 642
- May 9, 2018
healthcare India Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.